期刊文献+

胰岛素增敏剂防治非酒精性脂肪性肝病临床价值 被引量:12

Insulin sensitizers in treatment of nonalcoholic fatty liver disease.
原文传递
导出
摘要 非酒精性脂肪性肝病(NAFLD)已成为国内外常见慢性肝脏疾病之一,由于胰岛素抵抗在NAFLD发病机制中的重要作用,胰岛素增敏剂逐渐成为有前景的NAFLD治疗药物。本文分析总结了近年来胰岛素增敏剂治疗NAFLD的文献,结果提示,吡格列酮(PGZ)、罗格列酮(RGZ)和二甲双胍(MF)均能改善NAFLD患者肝酶水平和胰岛素抵抗;在改善肝脏组织学方面,PGZ有随机双盲对照研究证据的支持,显示出良好的应用前景;而MF与RGZ,缺少有力的人体研究支持。大多数研究中患者可以耐受胰岛素增敏剂,未见明显不良反应。目前已有研究的样本量均不大,疗程大多不超过2年,因此,仍需要设计良好的临床试验来进一步评价胰岛素增敏剂对NAFLD的疗效和安全性。 Nonalcoholic fatty liver disease ( NAFLD ) has become one of the most common liver diseases in the world. Considering the important role of insulin resistance in its pathogenic mechanisms,insulin sensitizers are becoming the promising pharmacological strategies for NAFLD. We collected and analyzed the relevant articles in recent years and found that pioglitazone,rosiglitazone and metformin could improve liver enzymes and insulin sensitivity of NAFLD. However, only pioglitazinc was supported in ameliorating liver histology by envidences from randomized, double-blinded, controlled clinical trials. There were no much obvious adverse effects in NAFLD patients who received insulin senitizers. Small or medium samples and no more than 2 years of treatment course may be the major limitation of current studies. Future information derived from well- designed running trials will be useful in defining the clinical implications of insulin sensitizers in the treatment of NAFLD.
作者 颜红梅 高鑫
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2009年第5期405-409,共5页 Chinese Journal of Practical Internal Medicine
关键词 非酒精性脂肪性肝病 胰岛素抵抗 胰岛素增敏剂 nonalcoholic fatty liver disease insulin resistance insulin sensitizer
  • 相关文献

参考文献19

  • 1Jiangao F, Jun Z, Xingjian L, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China [ J ]. J Hepatol,2005 ,43 :508 - 514.
  • 2Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome [ J ]. Hepatol,2003, 37(4) :917 -923.
  • 3刘蒙,颜红梅,高鑫,高键.非酒精性脂肪肝病患者中肝酶与代谢综合征的关系[J].中华医学杂志,2007,87(4):253-255. 被引量:21
  • 4颜红梅,高鑫,刘蒙,顾迁,张斌,李湘.肝脏脂肪含量与胰岛素抵抗及代谢综合征[J].中华医学杂志,2008,88(18):1255-1258. 被引量:13
  • 5Korenblat KM, Fabbrini E, Mohammed BS, et al.Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects [ J ]. Gastroenterology, 2008, 134(5 ) : 1369 - 1375.
  • 6Loomba R, Lutchman D, Kleiner E, et al. Clinical trial : pilot study of metformin for the treatment of non-alcoholic steatohepatitis [ J ].Aliment Pharmacol Ther,2008,29 ( 2 ) : 172 - 182.
  • 7Duseja A, Das A, Dhiman RK, et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD)not responding to lifestyle interventions [J]. Ann Hepatol,2007,6(4) :222 -226.
  • 8Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease [ J]. Acta Diabetol,2008 [ Epub ahead of print].
  • 9Valerio N, Melania M, Paolo C, et al. Mefformin Use in Children with nonalcoholic fatty liver disease : an open-Label, 24-month, observational pilot study [ J ]. Clinical Therapeutics, 2008,30 ( 6 ) : 1168 - 1176.
  • 10Elisabetta B, Elena G, Rita M, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver Disease [ J ]. Am J Gastroenterol, 2005, 100 ( 5 ) : 1082 - 1090.

二级参考文献13

  • 1Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量:1513
  • 2颜红梅,高鑫,刘蒙,顾迁,张斌,李湘,高键,赵耐青.非酒精性脂肪肝与代谢综合征关系的研究[J].中国糖尿病杂志,2006,14(5):326-328. 被引量:74
  • 3颜红梅,高鑫,刘蒙,顾迁,高键.糖调节正常的非酒精性脂肪肝病患者β细胞功能与胰岛素敏感性变化[J].中华内分泌代谢杂志,2007,23(1):12-15. 被引量:13
  • 4Marchesini G,Bugiansi E,Forlani G,et al.Nonalcoholic fatty liver,steatohepatitis,and the metabolic syndrome.Hepatology,2003,37:917-923.
  • 5Nannipieri M,Haffner SM,Ferrannini E,et al.Liver enzymes,the metabolic syndrome and incident diabetes:the mexico city Diabetes Study.Diabetes Care,2005,28:1757-1762.
  • 6Schindhelm RK,Diamant M,Bakker SJL,et al.Liver alanine aminotransferase,insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus.Eur J Clin Invest,2005,35:369-374.
  • 7Hanley AJ,Williams K,Haffner SM,et al.Elevations in markers of liver injury and risk of type 2 diabetes the insulin resistance atherosclerosis Study.Diabetes,2004,53:2623-2632.
  • 8Dixon JB,Bhathal PS,O' Brien PE.Nonalcoholic fatty liver disease:predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.Gastroenterology,2001,121:91-100.
  • 9Expert panel on detection,evaluation,and treatment of high blood cholesterol in adults.Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ).JAMA,2001,285:2486-2497.
  • 10Adams LA,Angulo P,Keith D,et al.Nonalcoholic fatty liver disease.CMAJ,2005,172:899-905.

共引文献32

同被引文献77

引证文献12

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部